OncoMatch/Clinical Trials/NCT04535713
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Is NCT04535713 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Gemcitabine and Doxorubicin for sarcoma.
Treatment: Gemcitabine · Doxorubicin · Docetaxel · Nivolumab — This is an open label phase 2 study for advanced sarcoma using metronomic doses of gemcitabine, doxorubicin and docetaxel, and nivolumab immunotherapy given intravenously.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC >1000 cells/μL; Platelet count >100,000/μL; Hemoglobin > 9.0 g/dL
Kidney function
Creatinine < 1.5 x ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula
Liver function
Bilirubin < 1.5 x ULN (except Gilbert Syndrome < 3.0 ULN); AST, ALT, alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)
Cardiac function
LV ejection fraction of > 50%
Acceptable cardiac function with LV ejection fraction of > 50%; Acceptable liver function: Bilirubin < 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present); Acceptable renal function: Creatinine < 1.5 times ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula; Acceptable hematologic status: ANC >1000 cells/μL; Platelet count >100,000/μL; Hemoglobin > 9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sant P Chawla · Santa Monica, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04535713 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages